Open AccessSignificance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
Author(s) -
Jun Teishima,
Daiki Murata,
Kazuma Yukihiro,
Yohei Sekino,
Shogo Inoue,
Tetsutaro Hayashi,
Koji Mita,
Yasuhisa Hasegawa,
Masaru Kato,
Mitsuru Kajiwara,
Masanobu Shigeta,
Shigeo Maruyama,
Hiroyuki Moriyama,
Seiji Fujiwara,
Akio Matsubara
Publication year - 2022
Publication title -
current urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.476
H-Index - 13
eISSN - 1661-7657
pISSN - 1661-7649
DOI - 10.1097/cu9.0000000000000105
Subject(s) - nivolumab , medicine , renal cell carcinoma , hazard ratio , oncology , carcinoma , multivariate analysis , second line , urology , gastroenterology , first line , cancer , immunotherapy , confidence interval
This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma.